Unmodified drug used as a material to construct nanoparticles: delivery of cisplatin for enhanced anti-cancer therapy
about
Current and Future Theranostic Applications of the Lipid-Calcium-Phosphate Nanoparticle Platform.Exploring the tumor microenvironment with nanoparticlesCo-delivery of cisplatin and rapamycin for enhanced anticancer therapy through synergistic effects and microenvironment modulation.Turning a water and oil insoluble cisplatin derivative into a nanoparticle formulation for cancer therapy.Co-delivery of polymeric metformin and cisplatin by self-assembled core-membrane nanoparticles to treat non-small cell lung cancer.Nanoparticles with Precise Ratiometric Co-Loading and Co-Delivery of Gemcitabine Monophosphate and Cisplatin for Treatment of Bladder Cancer.Engineering of lipid prodrug-based, hyaluronic acid-decorated nanostructured lipid carriers platform for 5-fluorouracil and cisplatin combination gastric cancer therapyNanoparticle modulation of the tumor microenvironment enhances therapeutic efficacy of cisplatin.Anti-tumor Efficiency of Lipid-coated Cisplatin Nanoparticles Co-loaded with MicroRNA-375Enhancing Nanoparticle Accumulation and Retention in Desmoplastic Tumors via Vascular Disruption for Internal Radiation Therapy.Nanotechnology in the management of cervical cancer.Nanoparticle formulations of cisplatin for cancer therapy.DOPA-based paclitaxel-loaded liposomes with modifications of transferrin and alendronate for bone and myeloma targeting.Organic nanoparticle systems for spatiotemporal control of multimodal chemotherapy.Preparation and evaluation of lipid emulsified docetaxel-loaded nanoparticles.Targeting Nanocarriers with Anisamide: Fact or Artifact?Nanoformulations for combination or cascade anticancer therapy.Efficient synthesis of a maghemite/gold hybrid nanoparticle system as a magnetic carrier for the transport of platinum-based metallotherapeutics.Targeted nanotherapeutics in cancer.Skin cancer: symptoms, mechanistic pathways and treatment rationale for therapeutic delivery.A nanocomplex of C60 fullerene with cisplatin: design, characterization and toxicity.Lipid-coated calcium phosphate nanoparticle and beyond: a versatile platform for drug delivery.A nanocomplex of C60 fullerene with cisplatin: design, characterization and toxicity.Strategies to improve micelle stability for drug delivery
P2860
Q26746186-F304840F-4FED-4FF7-AC6E-567689303FC3Q28082374-755E6D35-3B4C-47A1-885C-411D29F95D3FQ33716011-76E2062C-3444-4AD0-BC2F-528B4C15C361Q33827802-6D2BEF17-0819-43D8-8DF0-34F319D83633Q33915162-96F173E4-9262-4962-9695-3353D08D331DQ34479313-CD023CAD-DE66-49E9-9981-64A9233F7558Q35746919-2B210138-DAC0-4DE1-A1FA-D6CC0368F7D2Q36217643-E08AC607-A51B-4746-AA08-7BA81DF5719EQ36372357-70ED702D-312C-4199-837B-B411AA69B19EQ37541971-41CCA789-2183-45B3-9C1A-9FC1B9D3D95CQ38370785-21DDA636-A000-43CD-8D8A-94770E5503FEQ38723829-9146F048-43B9-4D24-84C6-3C755634840FQ38740618-D728B05D-F168-4586-BF7E-7733BC964B05Q38836010-F35A7165-1458-4629-94A7-887002086D59Q38845107-72A900EA-9575-4280-90A2-3B71E72B6351Q39019352-13233389-2525-4A55-8A25-139FEB62FCBAQ39380111-4B6EB921-93BB-4143-A514-8BB95900EF2FQ41908410-998A75E0-CBDE-491C-B587-B833F2C033F7Q42385386-3F20A7AC-887D-4927-A91B-722A08DDC543Q42507904-9A2398F6-77EF-45E8-BE68-E78AB86E6FB0Q47147900-36992704-672D-42C3-872B-269951024DD4Q47274570-3DD84EBC-0E55-496E-8BD3-256C970A8637Q47682144-6FD2DEB6-4D48-43D0-81D0-7B0FEAC7FC76Q58125662-C3E44C49-743D-4746-AEC8-066D67E17A75
P2860
Unmodified drug used as a material to construct nanoparticles: delivery of cisplatin for enhanced anti-cancer therapy
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Unmodified drug used as a mate ...... r enhanced anti-cancer therapy
@en
Unmodified drug used as a mate ...... enhanced anti-cancer therapy.
@nl
type
label
Unmodified drug used as a mate ...... r enhanced anti-cancer therapy
@en
Unmodified drug used as a mate ...... enhanced anti-cancer therapy.
@nl
prefLabel
Unmodified drug used as a mate ...... r enhanced anti-cancer therapy
@en
Unmodified drug used as a mate ...... enhanced anti-cancer therapy.
@nl
P2093
P2860
P1476
Unmodified drug used as a mate ...... r enhanced anti-cancer therapy
@en
P2093
P2860
P304
P356
10.1016/J.JCONREL.2013.11.019
P407
P50
P577
2013-11-23T00:00:00Z